Revolution Medicines
Price & Volume
Stats
See moreOpen | $205.92 |
Previous Close | $205.89 |
Day Range | $204.07-$208.80 |
52W Range | $45.80-$224.31 |
Market Cap | $43.9B |
Shares Short | 9M |
Financials
See moreRevenue (12 Mos) | $742,000 |
Revenue Growth (YoY) | -95.2% |
Gross Profit (12 Mos) | -$1.2B |
Diluted EPS | -$8.86 |
News
See moreYahoo Finance • 4 days ago
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Yahoo Finance • 10 days ago
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
Yahoo Finance • 16 days ago
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift
Yahoo Finance • 28 days ago
Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?
About
CEO | Dr. Mark A. Goldsmith M.D., Ph.D. |
Address | 700 Saginaw Drive, Redwood City, CA, United States, 94063 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 883 |